KIDney Injury in Times of COVID-19 (KIDCOV)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of California, San Francisco
About this trial
There is an unmet need to evaluate the impact of sub-clinical/mild COVID19 disease in the outpatient setting on prevalent and incident renal injury, as this data is currently unavailable. To capture the diversity of race/ethnic risk and COVID19 related municipal shelter-in-place guidance, the investigators will enroll COVID19-negative and COVID19-positive samples balanced by race/ethnicity from 3 different states, California, Michigan, and Illinois. Study endpoints will be assayed from urine samples mailed to the study team at 2, 6, and 12 months after their date of PCR test, with no requirement for these individuals to leave their homes to participate.
Eligibility criteria
Qualifiers
Result of PCR-based COVID-19 test conducted in the past 4 weeks posted in EMR of participating AMC
Age 18 years or older at enrollment
Race/ethnicity, sex, age, and phone and/or home/email address provided
Disqualifiers
Failure of a candidate participant to give written informed consent to comply with the study protocol
Hospitalization up to 4 weeks after SARS-CoV-2 test
History of kidney transplant
History of dialysis
Trial design
Treatments tested in this trial
- Urine Collection
Treatment groups
2,000 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of California, San Francisco
Lead sponsor
Rush University Medical Center
Collaborator
University of Michigan
Collaborator
University of California
Collaborator
Source ClinicalTrials.gov